Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C38H50O6 |
| Molecular Weight | 602.8 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=C)[C@@H](CC=C(C)C)C[C@]12C[C@@H](CC=C(C)C)C(C)(C)[C@](CC=C(C)C)(C(=O)C(C(=O)C3=CC(O)=C(O)C=C3)=C1O)C2=O
InChI
InChIKey=QDKLRKZQSOQWJQ-MZBNNVTPSA-N
InChI=1S/C38H50O6/c1-22(2)11-13-27(25(7)8)20-37-21-28(15-12-23(3)4)36(9,10)38(35(37)44,18-17-24(5)6)34(43)31(33(37)42)32(41)26-14-16-29(39)30(40)19-26/h11-12,14,16-17,19,27-28,39-40,42H,7,13,15,18,20-21H2,1-6,8-10H3/t27-,28+,37?,38?/m0/s1
| Molecular Formula | C38H50O6 |
| Molecular Weight | 602.8 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/npp/garcinol.htmlCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28598692 | https://www.ncbi.nlm.nih.gov/pubmed/28302538 | https://www.ncbi.nlm.nih.gov/pubmed/19101154 | https://www.ncbi.nlm.nih.gov/pubmed/25634295
Sources: https://www.drugs.com/npp/garcinol.html
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28598692 | https://www.ncbi.nlm.nih.gov/pubmed/28302538 | https://www.ncbi.nlm.nih.gov/pubmed/19101154 | https://www.ncbi.nlm.nih.gov/pubmed/25634295
Garcinol is a polyisoprenylated benzophenone derivative from the rind of Garcinia indica fruit and is a potent inhibitor of histone acetyltransferases. Garcinol is primarily present in family Clusiaceae and genus Garcinia . Although Garcinia indica is commonly referenced in the scientific literature, it is found in other plant species. Numerous in vitro and scientific animal studies on garcinol document anti-inflammatory, antioxidant, anticancer, and antibacterial activity. In preclinical study Topical application or oral administration of garcinol inhibited TPA-induced ear inflammation in a dose-dependent manner in CD-1 mice. TPA-induced expression of proinflammatory cytokine IL-6 protein was inhibited by topical application of garcinol to the ears of CD-1 mice. UVB-induced ear inflammation and proinflammatory cytokines IL-1 beta and IL-6 were inhibited in mice after oral administration of garcinol. Topical application of garcinol strongly inhibited TPA-induced skin tumor promotion in mice. Garcinol is used as an active ingredient in various topical products for its antioxidant activity. It is also used as an additive ingredient in hydroxycitric acid, purported by some commercial manufacturers to improve lean body mass.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3784 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25634295 |
1.7 µM [IC50] | ||
Target ID: CHEMBL5500 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19101154 |
6.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28598692
Rat: oral 10-20 mg/kg body weight/day for one month
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21776480
Cell viability was assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT). Hep3B, HepG2, A431, MCF-7, and COLO205 cellswere plated into 24 well plates at a density of 1 x 10^5 cells per well. After overnight growth, cells were treated with a series of garcinol concentrations for 24 h. The final DMSO concentration in the culture medium was <0.05%. At the end of treatment, 30 mL of MTT was added, and the cells were incubated for 4 h. Cell viability was determined by scanning with an enzyme-linked immunosorbent assay reader at 570 nm
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:33:22 GMT 2025
by
admin
on
Mon Mar 31 22:33:22 GMT 2025
|
| Record UNII |
TR1VR1V71B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
TR1VR1V71B
Created by
admin on Mon Mar 31 22:33:22 GMT 2025 , Edited by admin on Mon Mar 31 22:33:22 GMT 2025
|
PRIMARY | |||
|
DTXSID201025617
Created by
admin on Mon Mar 31 22:33:22 GMT 2025 , Edited by admin on Mon Mar 31 22:33:22 GMT 2025
|
PRIMARY | |||
|
78824-30-3
Created by
admin on Mon Mar 31 22:33:22 GMT 2025 , Edited by admin on Mon Mar 31 22:33:22 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |